StockData
Entrada Therapeutics, Inc. logo

Entrada Therapeutics, Inc. (TRDA) stock

TRDANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$5.03+0.07 (+1.41%)

Close on Nov 18, 2026Market cap $195.85MP/E –Yield –

Entrada Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Entrada Therapeutics's pe ratio was 7.3× on Jul 31, 2025, against 27.9× a year earlier.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2025Jul 31, 20257.3×−3.9
2024Dec 31, 202411.2×–

More Entrada Therapeutics figures

See a number that looks wrong?